1. Home
  2. BELFA vs ADPT Comparison

BELFA vs ADPT Comparison

Compare BELFA & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bel Fuse Inc.

BELFA

Bel Fuse Inc.

HOLD

Current Price

$193.19

Market Cap

2.3B

Sector

N/A

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$13.92

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BELFA
ADPT
Founded
1949
2009
Country
United States
United States
Employees
4964
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.0B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
BELFA
ADPT
Price
$193.19
$13.92
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$17.78
AVG Volume (30 Days)
53.7K
2.0M
Earning Date
04-23-2026
04-30-2026
Dividend Yield
0.12%
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
N/A
$276,976,000.00
Revenue This Year
$28.52
$3.98
Revenue Next Year
$7.85
$22.72
P/E Ratio
$40.02
N/A
Revenue Growth
N/A
54.77
52 Week Low
$53.95
$6.68
52 Week High
$227.42
$20.76

Technical Indicators

Market Signals
Indicator
BELFA
ADPT
Relative Strength Index (RSI) 49.54 42.34
Support Level $114.22 $12.24
Resistance Level $227.42 $17.52
Average True Range (ATR) 8.94 0.67
MACD 1.53 0.10
Stochastic Oscillator 62.13 61.61

Price Performance

Historical Comparison
BELFA
ADPT

About BELFA Bel Fuse Inc.

Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: